Mesothelioma treatment: from hopeless to hopeful
Recipient of the Heine H. Hansen Award 2023, Prof. Paul Baas charts the course of mesothelioma treatment over the last 30 years and warns that progress has been made only in some areas of the world
First-line immunotherapy prolongs survival in advanced or recurrent endometrial cancer
Results from the RUBY trial show improvements both in progression-free survival and overall survival in patients treated with dostarlimab plus standard chemotherapy, indicating a new standard of care
Promising advances in the molecular landscape of NETs
Molecular genetic analyses of NETs hint at actionable therapeutic targets and potential predictive biomarkers of response to axitinib
Patients as partners to address unmet needs in sarcoma
However, there are still many obstacles faced by investigators in achieving effective patient involvement in research
New findings help guide management of appendix adenocarcinoma
Database studies in this rare cancer suggest that chemotherapy may provide survival benefit in node-positive tumours and that the KRAS G12D mutation could be a potential therapeutic target
Early phase cancer research – ready for a change?
New recommendations of the MDICT Taskforce highlight the need to rethink how research studies are conducted and of multi-stakeholder collaboration
Epigenetic therapies – have they come of age?
The 2023 ESMO TAT Honorary Awardee Prof. Susan E. Bates gives an overview of the lasting challenges and unfulfilled potential of these therapies
National cancer registries in Asia – is Big Data the way to go?
Integrated, comprehensive databases may help to close the gap in cancer care between high- and low-/lower-middle-income countries
Rare cancers in Asia – the value of registry data in low-resourced settings
While some challenges associated with rare cancers are similar in Europe and Asia, resources and differing epidemiology need to be considered when coming up with solutions
Equity among oncologists is far from being achieved in the Chinese culture
Results from a pilot study show that work–family balance is the biggest challenge to career progression for young women